switching between glp-1 agonists chart GLP‐1 receptor in clinical practice: Expert consensus and practical guidance - Jain - 2021 - International Journal of Clinical Practice Switching GLP-1 injection providers for

GLP-1 as a treatment for weight loss seems to have become all the rage these days

However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors

As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)

Ph 2 datathat showed weight loss of between 9.4% and 14.7% after 36 weeks on the drug compared to 2.3% for the placebo group and is currently in Ph 3

In separate group of rats after coronary artery ligation selective afferent renal denervation (A-RDN) was performed by periaxonal application of capsaicin, then intravenous infusion of GLP-1-induced diuresis and natriuresis were evaluated

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)